Parallax Volatility Advisers
MACK

Parallax Volatility Advisers’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Parallax Volatility Advisers’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,509
Closed -$20K – 5317
2017
Q4 		$20K Buy
+2,509
New +$23.4K ﹤0.01% 3681

Other funds holding MACK

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Parallax Volatility Advisers's MACK Position: Q1 2018 in Review

Parallax Volatility Advisers sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2018, closing a stake of 2,509 shares — an estimated $20K sold.

Parallax Volatility Advisers first reported a position in MACK in Q4 2017 and held it in 1 quarter. The position peaked at $20K in Q4 2017. 81 funds tracked by Wall St. Rank hold MACK as of Q1 2018.

  • Parallax Volatility Advisers reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 2,509 Merrimack Pharmaceuticals, Inc. shares in Q1 2018, an estimated $20K.
  • Parallax Volatility Advisers first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2017 and held it in 1 quarter.
  • Parallax Volatility Advisers's Merrimack Pharmaceuticals, Inc. position peaked at $20K in Q4 2017.
  • 81 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2018.

Based on Parallax Volatility Advisers's 13F filing for Q1 2018, filed 15 May 2018.